GlyTherix Ltd | LinkedIn (original) (raw)
``
Biotechnology
Macquarie Park, New South Wales 1,018 followers
Highly targeted cancer therapy and imaging.
About us
GlyTherix Ltd, is a targeted radiotherapy company with a clinical stage antibody product, Miltuximab®, showing an excellent safety profile in high unmet need cancers. Miltuximab® specifically targets GPC-1, a protein found on solid tumours such as prostate, bladder, pancreatic, glioblastoma, oesophageal and ovarian cancers, and is not present in healthy tissue. There is a large addressable market in the USA and Europe of US$21.7 billion per annum. The company has a strong proprietary and intellectual property position covering the Miltuximab® antibody, epitope and the antigen. This provides robust and long-term protection for the commercialization of important new treatments to people with little hope. Miltuximab® precisely delivers targeted radiation to cancer cells. The company chelates a low energy 89Zirconium isotope to the antibody for diagnostic imaging. Image positive patients can then receive a dose of Miltuximab® that is chelated to the high energy isotope 177Lutetium resulting in a cell destroying dose directly at the site of the cancer. GlyTherix also has a pre-clinical program underway investigating the use of alpha particles, ie 225Actinium and 212Lead. GlyTherix has completed a ‘First-in-Human’ trial of 12 patients using Miltuximab® with no drug-related adverse. events. Miltuximab® will be used in both the Phase Ib and US Phase 2 trials as an antibody theranostic. The company has entered an exclusive manufacturing, supply & distribution agreements with reliable isotope suppliers ANSTO and Cyclowest Holdings, both highly regarded nuclear medicine companies in Australia. Agreements with US based CDMOs and isotope suppliers for our planned US trials are also in place. GlyTherix has a strong management and research team and a highly experienced clinical advisory panel who have been intimately involved in commercialisation of targeted radiotherapies that are marketed in the US and elsewhere.
Industry
Biotechnology
Company size
2-10 employees
Headquarters
Macquarie Park, New South Wales
Type
Privately Held
Founded
2017
Specialties
immuno-oncology company, therapeutics for solid tumors, and targeted treatment of prostate, bladder and pancreas cancers
Locations
Employees at GlyTherix Ltd
Updates
- We will be presenting an e-poster titled "Determination of Optimal Imaging Dose of [89Zr]Zr-DFO-Miltuximab and Maximum Tolerated Therapeutic Dose of [177Lu]Lu-DOTA-Miltuximab." Join us to explore groundbreaking research in the field of dosimetry and radiobiology. 📅 Dates: October 19-23, 2024 📍 Location: Hamburg, Germany 🔖 Session Title: D: Technical Studies -> D4 Dosimetry and Radiobiology -> D42 Clinical Dosimetry 📌 e-Poster Number: EP-0916 🕒 Session Number: EP-58. We look forward to sharing our findings and discussing the potential impact on enhancing diagnostic and therapeutic precision in cancer treatment. Don’t miss out on this insightful presentation during the congress opening hours! https://eanm24.eanm.org/ #EANM24 #NuclearMedicine #CancerResearch #GlyTherix #Dosimetry #Radiobiology #MedicalInnovation
-
CEO at Minomic International Ltd and GlyTherix Ltd Serial Entrepreneur
1mo
Thanks Melissa Benson for giving GlyTherix Ltd a shout out in your recent Phase III podcast!
Wilson's Advisory equity analyst Dr Melissa Benson
https://www.youtube.com/
- Exciting News in Targeted Radiotherapy! GlyTherix Ltd has signed a global clinical supply agreement with Eckert & Ziegler SE, a leader in isotopes for nuclear medicine. This collaboration will provide GMP-grade Lutetium-177 chloride for GlyTherix's clinical trials, aimed at treating aggressive cancers through innovative antibody radiopharmaceuticals. GlyTherix’s approach utilizes Lu-177 combined with an antibody targeting Glypican-1, a protein prevalent in several aggressive cancers, allowing for localized radiation treatment while protecting healthy tissue. Clinical trials are set to kick off in Australia in early 2025, followed by U.S. trials in 2026. Dr Brad Walsh, CEO of GlyTherix, emphasized the importance of this partnership in further strengthening their global supply network, ensuring high-quality isotopes are available for patients. Dr. Harald Hasselmann, CEO of Eckert & Ziegler, echoed this sentiment, expressing enthusiasm for supporting groundbreaking treatments. Together, we’re paving the way for the future of cancer therapy! Read the media release here:https://lnkd.in/grX2vSmW #TargetedTherapy #Lutetium177 #InnovationInHealthcare
- GlyTherix is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE Technologies, a pioneer in next-generation fusion-based technology and North America's largest producer of non-carrier added lutetium-177 (n.c.a. Lu-177) chloride. SHINE will supply its n.c.a. Lu-177 chloride, Ilumira, for use in GlyTherix's clinical trials focused on innovative treatments for aggressive and invasive cancers. Greg Piefer, SHINE founder and CEO commented, “GlyTherix's innovative approach has the potential to transform cancer care for patients with some of the most challenging solid tumors. By providing a reliable supply of high-quality Ilumira, we're proud to support their groundbreaking work that could offer new hope to patients with limited treatment options." Read the Media Release here: https://lnkd.in/gRh6izdn #cancertreatment #aggressivecancer #solidtumor Bernadette van Heerden David Bailey
- GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the manufacture of GlyTherix’s targeted radiotherapy antibody products for its US clinical trials. Under the terms of the agreement, 3DI will manufacture and deliver finished clinical unit doses of GlyTherix’s imaging and therapeutic products (89Zr-Miltuximab® and 177Lu-Miltuximab®) from 3DI’s central facility in Little Rock, Arkansas, USA located close to the Global FedEx hub. 3DI will also supply its own cyclotron-produced GMP Zirconium-89 oxalate product for the manufacture of 89Zr-Miltuximab®. The agreement is structured to support GlyTherix’s US manufacturing needs and incorporates potential future product distribution requirements in the Asia-Pacific region. Read the media release here: https://lnkd.in/gygVmyMG #ClinicalTrials #radiotherapy #radiopharmaceuticals #antibody #solidtumors Marc Berridge